Santa Monica, CA and Salt Lake City, UT (PRBUZZ) July 12th, 2017 – Leonhardt’s Launchpads is pleased to announce a number its portfolio companies will be presenting at the upcoming International Academy of Cardiology World Congress of Heart Disease in Vancouver, Canada July 14th to 16th.
BioLeonhardt has been selected to present pre-clinical data on regenerating damaged hearts using a combination technology of bioelectric stimulation and repeat delivery of a mixed composition of stem cells + growth factors. The combination product is comprise of (1) bioelectric stimulation-controlled stem cell homing, proliferation and differentiation signals and controlled release of over 15 heart regeneration promoting proteins such as SDF-1, IGF-1, HGF, EGF, PDGF, VEGF, eNOS, HIF-1 alpha, IL-6, Activin A+B, Follistatin, and Tropoelastin; (2) a re-fillable implantable, programmable micro infusion pump; and (3) a mixed composition of myogenic stem cells, growth factors, exosomes, micro RNAs, selected alkaloids, anti-inflammatory agents, heart matrix and nutrient hydrogel.
Second Heart Assist, Inc. has been selected to present pre-clinical lab data and its innovative new designs for circulatory assist support. Second Heart Assist, Inc. has developed two products for circulatory support:
1. Temporary circulatory support pump within an aortic stent on the tip of a catheter placed just above the renal arteries in the descending aorta combined with a removable wireless powered pulsatile mesh stent which is placed above the catheter higher in the aorta.
2. Chronic circulatory assist device (removable) within an aortic stent wireless powered with vibrational harmonic energy technology to prevent blood clot formation. Device features both a turning impeller within a lower positioned aortic stent and a pulsating cuff aortic stent which is placed above the primary stent pump.
Details for Presentations are as follows:
Saturday July 15th, 2017
Poster Hall – Hyatt Regency
8;00am MECHANICAL DEVICE FOR THE MANAGEMENT OF CARDIO-RENAL SYNDROME
041 Dr L.W. Miller Leonhardt Ventures for Second Heart Assist, Inc.
14:00 – 16:45 Hall B PL13 Plenary Session V – Hyatt Regency
VASCULAR REMODELING AND CARDIAC REGENERATION AND REPAIR SESSION V
Chair: A.M. Gerdes
15:45pm BIOELECTRIC STIMULATION FOR ORGAN REGENERATION (Invited Lecture) 200
Dr. L.W. Miller, Leonhardt Ventures for BioLeonhardt, Valvublator and VascuStim
“We are excited to present some of our breakthrough technologies at this prestigious conference. We believe both our bioelectric + repeat delivery via micro infusion pump cell and growth factors composition for organ regeneration and our Second Heart Assist device for circulatory assist support are on a pathway to greatly improve patient outcomes. We are designing and implementing well controlled studies at leading institutions worldwide to demonstrate the safety and efficacy of these products. We look forward to reporting first-in-man clinical results in 2018”, stated Dr. Leslie Miller, Chief Medical Officer. Dr. Miler will be presenting the Second Heart Assist and BioLeonhardt data at the upcoming World Congress of Heart Disease.
In addition, Dr. Miller will briefly introduce Leonhardt’ Valvublator technology for minimally invasive heart valve decalcification and regeneration T, as well as the Vascustim product for treating diabetic leg and foot ulcers, CLI and limb salvage.
About Leonhardt Ventures: Founded in 1982 Leonhardt Ventures (Leonhardt Vineyards LLC DBA Leonhardt Ventures) developed in the 1980’s world leadership in the development of cardiovascular balloon catheters, in the 1990’s aortic stent grafts and percutaneous heart valves, and since 2000 the organization has focused on developing organ regeneration technologies based on bioelectric stimulation and repeat delivery of mixed stem cell based compositions. The team led the first ever stem cell repair of a human heart without open chest surgery in The Netherlands, May 2001. See www.leonhardtventures.com ;
About Second Heart Assist, Inc.: Founded by Leonhardt Ventures in 2015 Second Heart Assist, Inc. a Utah C corporation is focused in the development of both temporary catheter based and wireless powered chronic implant circulatory assist pumps. Second Heart announced a series of announcements the first half of 2017: (1) a major patent option licensing agreement with the California Institute of Technology (Caltech) for a full estate of patents covering pulsatile flow wireless powered pumps within stents, (2) filing of its own provisional patent application for harmonic resonance vibration technology to prevent blood clot, plaque and calcification formations on blood contact surfaces, and (3) an agreement with Biomerics Utah and Biomerics Advanced Catheter in Minnesota for engineering, prototype building and testing, quality control and manufacturing service. See www.secondheartinc.com .
About Leonhardt’s Launchpads: Founded in 2008 Leonhardt’s Launchpads operates organ regeneration and recovery focused incubators in Northern California, Southern California and Utah with the assistance of Cal-X Stars Business Accelerator, Inc a California C corporation based in Santa Monica, CA (majority owned by Leonhardt Ventures LLC, and Leonhardt’s Launchpads Utah, Inc., a Utah C corporation based in Salt Lake City, Utah). The Santa Monica based accelerator also is incubating 4 regenerative economy startups that channel 50% of profits to organ regeneration and recovery research. There are 26 regenerative medtech and 4 regenerative economy startups currently incubating in these incubator/accelerators. See www.calxstars.com + https://leonhardtventures.com/leonhardts-launchpads-utah/ + www.leonhardtventures.com ;
About BioLeonhardt: BioLeonhardt founded in 2012 focuseson heart regeneration with a combination of bioelectric stimulation and micro infusion pump repeat delivery of a mixed stem cell based composition. See www.bioleonhardt.com .
About Vavlublator: Vavlublator founded in 2013 focuses on development of a catheter based heart valve decalcification and regeneration device. The Leonhardt team previously invented, patented and developed the first percutaneous heart valve in the 1990s. See www.valvublator.com.
About VascuStim: Vascustim (formerly MyoStim Peripheral) founded in 2012 is a clinical stage startup focused on developing combination bioelectric stimulation and repeat delivery stem cell + growth factors composition for limb salvage, diabetic foot and leg ulcers and critical limb ischemia treatment. See https://leonhardtventures.com/vascustim
About World Congress of Heart Disease: See http://www.cardiologyonline.com/wchd2017/index.htm Program: http://www.cardiologyonline.com/wchd2017/final_prog_fri.html INTERNATIONAL ACADEMY OF CARDIOLOGY, ANNUAL SCIENTIFIC SESSIONS 2017, 22nd WORLD CONGRESS ON HEART DISEASE. Hyatt Regency, 1 Discovery Square, 655 Burrard Street, Vancouver, BC V6C 2R7, Canada
Forward-Looking Statements: This announcement contains or may contain forward-looking statements that are based on management’s beliefs, assumptions and expectations and on information currently available to management. All statements that are not statements of historical fact, including those statements that address future operating performance and events or developments that we expect or anticipate will occur in the future, are forward-looking statements, such as those statements regarding our ability to obtain regulatory approvals, timely and successfully complete our clinical trials, protect our intellectual property position, commercialize our products if and when approved, develop and commercialize new products, recruit and retain our key personnel, and estimates regarding our capital requirements and financial performance. You should not place undue reliance on forward-looking statements. Although management believes forward-looking statements are reasonable as and when made, forward-looking statements are subject to a number of risks and uncertainties that may cause our actual results to vary materially from those expressed in forward-looking statements, including the risks and uncertainties that are described in the “Risk Factors” section of our Annual Report and as may be updated in our periodic reports thereafter. Any forward-looking statements in this announcement speak only as of the date when made. Leonhardt’s Launchpads Utah, Inc, Leonhardt’s Launchpads by Cal-X Stars Business Accelerator, Inc., Leonhardt Ventures LLC, BioLeonhardt, Valvublator, Vascutim and Second Heart Assiset ,Inc. do not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Investors Relations: Asli Gozoren, Chief Advisor Investor Relations, firstname.lastname@example.org
Media: Brian Hardy, Director of Marketing, email@example.com
Clinical and Pre-Clinical Studies: Dr. Leslier Miller, Chief Medical Advisor, firstname.lastname@example.org
All Other Inquiries: Howard Leonhardt, Executive Chairman & CEO, email@example.com
Central Google Voice Mail: (424) 291-2133
Leonhardt’s Launchpads by Cal-X Stars, 2000 Main Street, Unit 333, Santa Monica, CA 90405 – www.leonhardtventures.com + www.calxstars.com
Leonhardt’s Launchpads Utah, Inc. 370 S, 300 E, Salt Lake City, UT 84111
Research Lab @ 2500 S State St. #224, Salt Lake City, UT 84115